Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry.
All entries for: Biologic
May 7, 2026
CytomX Therapeutics, Inc.
Neutral Outlook
San Francisco, CA
51-200 employees
For that and other reasons, it is currently unclear how the IRA will be effectuated. These laws and future laws may negatively impact the ability of biotechnology companies, including us, to raise funds from investors for or to obtain collaboration partners who assist us in the funding of research and development of future medicines.
Disease Area: Oncology
Drug Type: Biologic
May 7, 2026
Neumora Therapeutics, Inc.
Neutral Outlook
Waltham, Massachusetts,
51-200 employees
For that and other reasons, it is currently unclear how the IRA will be effectuated, and while the impact of the IRA on the biopharmaceutical industry cannot yet be fully determined, it is likely to be significant.
Disease Area: Neurological Diseases, Psychiatry
Drug Type: Biologic, Small Molecule
May 7, 2026
Corvus Pharmaceuticals, Inc.
Neutral Outlook
Burlingame, CA
51-200 employees
While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.
Disease Area: Dermatology, Hematology, Immune Diseases, Oncology
Drug Type: Biologic, Small Molecule
May 7, 2026
Gilead Sciences, Inc.
Negative Outlook
Foster City, CA
10,000+ employees
While the full impact of the IRA on our business and the pharmaceutical industry remains uncertain at this time, we anticipate that the IRA will increase our payment obligations under the redesigned Part D discount program, limit the prices we can charge for our products, and increase the rebates we must provide government programs for our products, thereby reducing our profitability and negatively impacting our financial results.
Disease Area: Antiviral, Chronic Disease, Multiple, Oncology
Drug Type: Biologic, Small Molecule
May 6, 2026
Biocryst Pharmaceuticals Inc
Negative Outlook
Durham, NC
501-1,000 employees
The IRA or other government efforts to reduce the price of prescription drugs or to limit the amount that governments pay for healthcare products and services could result in additional pricing pressure and have a significant impact on our business.
Disease Area: Rare Diseases
Drug Type: Biologic, Small Molecule
May 6, 2026
Tenaya Therapeutics, Inc.
Neutral Outlook
South San Francisco, CA
51-200 employees
While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run. The laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patent and the patents we might obtain or license in the future.
Disease Area: Cardiology, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
May 6, 2026
Sarepta Therapeutics
Neutral Outlook
Cambridge, MA
501-1,000 employees
For example, the Inflation Reduction Act (“IRA”), passed in 2022, IRA has had and will likely continue to have a significant impact on the pharmaceutical industry. In 2025, the current presidential administration issued two executive orders with multiple directives aimed at lowering drug prices.
Disease Area: Neurological Diseases, Rare Diseases
Drug Type: Biologic
May 6, 2026
GERON CORP
Neutral Outlook
Foster City, CA
51-200 employees
The Inflation Reduction Act of 2022 includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government, including the Medicare Drug Price Negotiation Program, which may ultimately have a negative effect on the pricing for RYTELO… These changes could lower reimbursement for Medicare Part B utilization and require manufacturers to comply with new, uncertain or complex reporting obligations and drug pricing documentation practices.
Disease Area: Hematology, Oncology
Drug Type: Biologic
May 6, 2026
Gilead Sciences
Layoffs
Foster City, CA
10,000+ employees
After closing its $7.8 billion takeover of Arcellx last week, Gilead Sciences is now letting go of 108 employees at the biotech’s headquarters in Redwood City, California, according to a Worker Adjustment and Retraining Notification (WARN) alert for the state. The layoffs will take effect on June 30.
Arcellx had 220 employees as of March 1, according to a securities filing last month, indicating that Gilead’s cuts will nearly halve the biotech’s workforce.
Gilead and Arcellx are long-time partners. The companies joined hands in December 2022, with the pharma paying $225 million upfront alongside a $100 million equity investment in the biotech. The deal was focused on Arcellx’s late-stage CAR T therapy—the asset that would later be named anito-cel—for the treatment for relapsed or refractory multiple myeloma. Gilead at the time pledged up to $3.9 billion in milestones.
Disease Area: Antiviral, Immune Diseases, Infectious Diseases, Multiple, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule